uniQure N.V. (QURE)Healthcare | Biotechnology | Amsterdam, Netherlands | NasdaqGS
17.58 USD
+0.77
(4.581%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 17.49 -0.09 (-0.090%) ⇩ (April 17, 2026, 7:41 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 7:52 p.m. EDT
This is a high-volatility contrarian play where the charts and options flow have decoupled from the fundamental disaster of a negative earnings outlook. Despite the company burning cash with no dividend and trading at a massive premium to sales, options speculators are piling into deep out-of-the-money calls, effectively treating the current ~$17 price as a floor for a potential squeeze. The fundamental story remains a 'wait and see' neutrality (Rating 3), but the short-term mechanics are screaming for a bullish momentum pop, likely driven by the recent buyback announcement and fading short interest. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.309297 |
| MSTL | 0.312471 |
| AutoETS | 0.313141 |
| AutoTheta | 0.365719 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 39.42 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.228 |
| Excess Kurtosis | 0.26 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 269.778 |
| Revenue per Share | 0.28 |
| Market Cap | 1,099,266,944 |
| Forward P/E | -6.45 |
| Beta | 0.75 |
| Website | https://www.uniqure.com |
As of April 18, 2026, 7:52 p.m. EDT: Speculators are heavily positioning for an upside breakout, evidenced by massive Open Interest (OI) concentration in out-of-the-money calls at $20, $22, and $30 across multiple expirations (May through 2028). Notably, a $30 strike in May saw volume (1.8k) significantly outpace open interest (529), indicating aggressive new money betting on a sharp reversal. While the $16-$18 strikes act as anchors, the skew towards higher strikes and the 'Major OI Wall' at $40 for July suggests traders expect a move well above the current $17.58 level. Put volume is present but largely concentrated in lower strikes ($10-$15), indicating downside hedging rather than a conviction in a crash, reinforcing a bullish sentiment structure.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.3227991 |
| Address1 | Paasheuvelweg 25 |
| All Time High | 82.49 |
| All Time Low | 3.73 |
| Ask | 21.79 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 1,591,480 |
| Average Daily Volume3 Month | 3,237,533 |
| Average Volume | 3,237,533 |
| Average Volume10Days | 1,591,480 |
| Beta | 0.747 |
| Bid | 12.67 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 3.191 |
| City | Amsterdam |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 4 |
| Country | Netherlands |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 17.58 |
| Current Ratio | 10.426 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 17.89 |
| Day Low | 17.015 |
| Debt To Equity | 269.778 |
| Display Name | uniQure |
| Earnings Call Timestamp End | 1,772,456,400 |
| Earnings Call Timestamp Start | 1,772,456,400 |
| Earnings Timestamp | 1,772,458,200 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -164,343,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.166 |
| Enterprise To Revenue | 62.947 |
| Enterprise Value | 1,013,318,016 |
| Eps Current Year | -2.9594 |
| Eps Forward | -2.7241979 |
| Eps Trailing Twelve Months | -3.46 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 17.923 |
| Fifty Day Average Change | -0.3430004 |
| Fifty Day Average Change Percent | -0.019137444 |
| Fifty Two Week Change Percent | 32.279907 |
| Fifty Two Week High | 71.5 |
| Fifty Two Week High Change | -53.92 |
| Fifty Two Week High Change Percent | -0.75412583 |
| Fifty Two Week Low | 8.73 |
| Fifty Two Week Low Change | 8.85 |
| Fifty Two Week Low Change Percent | 1.0137458 |
| Fifty Two Week Range | 8.73 - 71.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,391,610,600,000 |
| Float Shares | 49,188,134 |
| Forward Eps | -2.7241979 |
| Forward P E | -6.4532757 |
| Free Cashflow | -106,758,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 221 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -120,014,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.05608 |
| Held Percent Institutions | 1.02035 |
| Implied Shares Outstanding | 62,529,408 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands. |
| Long Name | uniQure N.V. |
| Market | us_market |
| Market Cap | 1,099,266,944 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_171029664 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -198,971,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,099,579,639 |
| Number Of Analyst Opinions | 11 |
| Open | 17.05 |
| Operating Cashflow | -177,963,008 |
| Operating Margins | -9.00934 |
| Overall Risk | 2 |
| Payout Ratio | 0.0 |
| Phone | 31 20 240 6000 |
| Post Market Change | -0.09000015 |
| Post Market Change Percent | -0.51194626 |
| Post Market Price | 17.49 |
| Post Market Time | 1,776,469,286 |
| Previous Close | 16.81 |
| Price Eps Current Year | -5.9403934 |
| Price Hint | 2 |
| Price To Book | 5.509245 |
| Price To Sales Trailing12 Months | 68.285934 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.988 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.69231 |
| Region | US |
| Regular Market Change | 0.77 |
| Regular Market Change Percent | 4.58061 |
| Regular Market Day High | 17.89 |
| Regular Market Day Low | 17.015 |
| Regular Market Day Range | 17.015 - 17.89 |
| Regular Market Open | 17.05 |
| Regular Market Previous Close | 16.81 |
| Regular Market Price | 17.58 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 1,842,055 |
| Return On Assets | -0.16206 |
| Return On Equity | -2.0710099 |
| Revenue Growth | 0.066 |
| Revenue Per Share | 0.28 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 62,529,408 |
| Shares Percent Shares Out | 0.17559999 |
| Shares Short | 10,981,448 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 12,617,484 |
| Short Name | uniQure N.V. |
| Short Percent Of Float | 0.1777 |
| Short Ratio | 2.32 |
| Source Interval | 15 |
| Symbol | QURE |
| Target High Price | 96.227104 |
| Target Low Price | 9.048849 |
| Target Mean Price | 38.523533 |
| Target Median Price | 35.292393 |
| Total Cash | 622,540,992 |
| Total Cash Per Share | 9.956 |
| Total Debt | 536,592,000 |
| Total Revenue | 16,098,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.46 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 25.277025 |
| Two Hundred Day Average Change | -7.6970253 |
| Two Hundred Day Average Change Percent | -0.30450678 |
| Type Disp | Equity |
| Volume | 1,842,055 |
| Website | https://www.uniqure.com |
| Zip | 1,105 BP |